Vical Inc Com (NASDAQ:VICL)

CAPS Rating: 1 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

VICL News and Commentary

Caps

How do you think VICL will perform against the market?

Add Stock to CAPS Watchlist

All Players

180 Outperform
18 Underperform
 

All-Star Players

27 Outperform
9 Underperform
 

Wall Street

6 Outperform
0 Underperform
 

Top VICL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

SqwiiTrader (< 20)
Submitted March 18, 2014

prediction TOS

zzlangerhans (99.74)
Submitted December 17, 2012

Vical has concluded yet again that patients in the phase III trial of Allovectin-7 are living longer than expected, resulting in another lengthy delay before topline data will be released. Naturally, Vical bulls see this as a positive, concluding… More

VICL VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about VICL.

Recs

1
Member Avatar SqwiiTrader (< 20) Submitted: 3/18/2014 7:03:47 PM : Outperform Start Price: $1.32 VICL Score: -44.95

prediction TOS

Recs

0
Member Avatar 10qdetective (< 20) Submitted: 3/4/2014 1:45:46 AM : Outperform Start Price: $1.51 VICL Score: -65.93

Potential buyer in Merck?

Vical (VICL) is developing Allovectin, a first-in-class investigational DNA-based immunotherapeutic designed to stimulate both innate and adaptive immune responses in local tumors and distal metastases.

Of unique interest to Merck is that this immunotherapy is currently being evaluated in late-stage clinical trials as first-line treatment for Stage III and IV melanoma. Merck watchers might want to know, too, that Vical’s current CEO, Vijay Samant, previously spent 20 years with Merck in international sales and marketing.

Recs

1
Member Avatar AndrewGreenBull (94.53) Submitted: 12/18/2013 11:37:30 AM : Outperform Start Price: $1.05 VICL Score: -35.82

With 2 approved products, a robust pipeline and 55 millions cash, VICL is a steal at current price $1.04.

Dengue Vaccine data will be released in this month according to ClinicalTrial. Should be back to $2 in days.

Leaderboard

Find the members with the highest scoring picks in VICL.

Score Leader

mjonesy1985

mjonesy1985 (96.04) Score: +551.87

The Score Leader is the player with the highest score across all their picks in VICL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
rhinomaj 92.71 8/4/2009 Underperform 3M $3.78 -65.61% +185.50% +251.11 0 Comment
etaster 42.79 12/3/2009 Underperform 1Y $2.92 -55.48% +156.19% +211.67 0 Comment
gogogoo 58.33 1/30/2007 Underperform 3Y $6.33 -79.62% +111.94% +191.56 0 Comment
FUZZYMINKINS < 20 7/11/2011 Underperform 5Y $4.29 -69.70% +114.83% +184.53 0 Comment
PIGMA 26.26 6/2/2011 Underperform 5Y $3.71 -64.96% +116.12% +181.08 0 Comment
elayton < 20 4/24/2008 Underperform 3W $3.63 -64.19% +115.80% +179.99 0 Comment
petricko 92.30 7/17/2007 Underperform 3W $5.15 -74.76% +93.54% +168.30 0 Comment
dwn88ir 58.32 4/23/2012 Underperform 5Y $2.83 -54.07% +108.87% +162.94 0 Comment
cIRCitmage < 20 2/8/2011 Underperform NS $2.03 -35.96% +115.91% +151.87 0 Comment
RafaelStock 98.80 8/1/2016 Underperform 5Y $4.14 -68.60% +31.31% +99.91 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBrinsonPatr < 20 6/18/2013 Outperform NS $2.98 -56.38% +73.34% -129.71 0 Comment
TrackCreditSuiss 88.88 5/13/2013 Outperform NS $3.54 -63.28% +74.75% -138.03 0 Comment
trackglobalhunte < 20 12/1/2011 Outperform NS $4.45 -70.79% +128.43% -199.21 0 Comment
TrackJohnRogers 59.25 9/23/2009 Outperform 1Y $4.40 -70.45% +165.74% -236.19 1 Comment
TrackTWeisel 87.28 6/12/2009 Outperform NS $3.05 -57.38% +205.25% -262.63 0 Comment
trackmerriman 68.89 12/20/2006 Outperform NS $6.59 -80.42% +112.60% -193.02 0 Comment

Featured Broker Partners


Advertisement